GlassScriptPhysician profile
Thomas D Ogara
NPI 1841287026
$7,147.65
in general payments reported to CMS, 2019-2025
44 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,039 · 2020: $273 · 2021: $1,171 · 2022: $1,864 · 2023: $1,176 · 2024: $1,309 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,801.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,742.92 | 2019-2025 | |
| Esperion Therapeutics, INC. | $865.31 | 2020-2024 | Nexletol |
| Glaxosmithkline, LLC. | $560.07 | 2022-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Astellas Pharma US INC | $435.98 | 2019-2024 | Veozah, Myrbetriq |
| Pfizer INC. | $405.86 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $397.10 | 2019-2024 | Jardiance |
| Amgen INC. | $255.21 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $211.77 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $204.72 | 2019-2024 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $190.81 | 2020-2022 | |
| Lucid Diagnostics INC. | $170.59 | 2023-2024 | |
| Amarin Pharma, INC. | $141.02 | 2019 | |
| Novo Nordisk INC | $125.84 | 2020-2025 | Wegovy |
| Intuitive Surgical, INC. | $117.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $107.30 | 2019-2023 | Eliquis |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ogara listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.